Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease

Blood

Volumn 130, Issue 19, 2017, Pages 2121-2130

  Meinderts, Sanne M ^a   Sins, Joep W R ^a   Fijnvandraat, Karin ^a,b   Nagelkerke, Sietse Q ^a   Geissler, Judy ^a   Tanck, Michael W ^a   Bruggeman, Christine ^a   Biemond, Bart J ^a   Rijneveld, Anita W ^c   Kerkhoffs, Jean Louis H ^d   Pakdaman, Sadaf ^e   Habibi, Anoosha ^f   Van Bruggen, Robin ^a   Kuijpers, Taco W ^a   Pirenne, France ^e   Van Den Berg, Timo K ^a,g  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HAGA HOSPITAL   (Netherlands)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIC; RHESUS ANTIBODY; RHESUS C ANTIBODY; RHESUS E ANTIBODY; UNCLASSIFIED DRUG; FCGR2C PROTEIN, HUMAN;

ADULT; AGED; ALLOIMMUNIZATION; ARTICLE; B LYMPHOCYTE; CASE CONTROL STUDY; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; FRANCE; GENE CLUSTER; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC VARIATION; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOGENICITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NATURAL KILLER CELL; NETHERLANDS; NEUTROPHIL; OPEN READING FRAME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; CLINICAL TRIAL; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; IMMUNIZATION; IMMUNOLOGY; MULTICENTER STUDY; MULTIGENE FAMILY; RISK FACTOR;

ADULT; ANEMIA, SICKLE CELL; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; FOLLOW-UP STUDIES; HAPLOTYPES; HUMANS; IMMUNIZATION; MALE; MULTIGENE FAMILY; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RISK FACTORS;

EID: 85033480453     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-05-784876     Document Type: Article

References (72)

1. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3): 528-537.
2. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169(5):746-753.
3. Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol. 2016;91(10):989-994.
4. Sins JWR, Biemond BJ, van den Bersselaar SM, et al. Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Am J Hematol. 2016;91(8):763-769.
5. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol. 2012; 159(4):394-404.
6. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):1617-1621.
7. LaSalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion. 2011;51(8):1732-1739.
8. Tahhan HR, Holbrook CT, Braddy LR, Brewer LD, Christie JD. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion. 1994;34(7):562-569.
9. O’Suoji C, Liem RI, Mack AK, Kingsberry P, Ramsey G, Thompson AA. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer. 2013;60(9): 1487-1491.
10. Vichinsky EP, Luban NL, Wright E, et al; Stroke Prevention Trail in Sickle Cell Anemia. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41(9): 1086-1092.
11. Mijovic A, Perera IGJ, Thein SL. Red blood cell alloimmunization in sickle cell disease-prevalence and trends: a single-center cross-sectional study from United Kingdom. Transfusion. 2013;53(12): 3279-3280.
12. Kacker S, Ness PM, Savage WJ, et al. Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion. 2014;54(1): 86-97.
13. Nickel RS, Horan JT, Fasano RM, et al. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol. 2015;90(12):1135-1141.
14. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062-1071.
15. Silvy M, Tournamille C, Babinet J, et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica. 2014;99(7):e115-e117.
16. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood. 2008;112(6):2546-2553.
17. Gehrie EA, Tormey CA. The influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: responders, hyper-responders, and non-responders. Transfus Med Hemother. 2014;41(6):420-429.
18. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673): 245-252.
19. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996; 383(6603):787-793.
20. Noizat-Pirenne F, Tournamille C, Bierling P, et al. Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis. Transfusion. 2006;46(8): 1328-1333.
21. Evers D, Middelburg RA, de Haas M, et al. Red-blood-cell alloimmunisation in relation to antigens’ exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016;3(6):e284-e292.
22. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015;168(2):291-300.
23. Ryder AB, Zimring JC, Hendrickson JE. Factors influencing RBC alloimmunization: lessons learned from murine models. Transfus Med Hemother. 2014;41(6):406-419.
24. Alarif L, Castro O, Ofosu M, Dunston G, Scott RB. HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clin Immunol Immunopathol. 1986;38(2):178-183.
25. Hoppe C, Klitz W, Vichinsky E, Styles L. HLA type and risk of alloimmunization in sickle cell disease. Am J Hematol. 2009;84(7):462-464.
26. Picard C, Frassati C, Basire A, et al. Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a southern European population. Transfusion. 2009;49(11):2412-2417.
27. Chiaroni J, Dettori I, Ferrera V, et al. HLA-DRB1 polymorphism is associated with Kell immunisation. Br J Haematol. 2006;132(3): 374-378.
28. Reviron D, Dettori I, Ferrera V, et al. HLA-DRB1 alleles and Jk(a) immunization. Transfusion. 2005;45(6):956-959.
29. Tatari-Calderone Z, Minniti CP, Kratovil T, et al. rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease. Mol Immunol. 2009;47(1):64-70.
30. Tatari-Calderone Z, Tamouza R, Le Bouder GP, et al. The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin Dev Immunol. 2013;2013:937846.
31. Amigorena S, Bonnerot C, Drake JR, et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science. 1992;256(5065):1808-1812.
32. Amigorena S, Salamero J, Davoust J, Fridman WH, Bonnerot C. Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature. 1992; 358(6384):337-341.
33. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.
34. Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149-177.
35. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity. 2000; 13(2):277-285.
36. Yuasa T, Kubo S, Yoshino T, et al. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med. 1999;189(1):187-194.
37. Nakamura A, Yuasa T, Ujike A, et al. Fcgamma receptor IIB-deficient mice develop Goodpasture’s syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med. 2000;191(5):899-906.
38. Haberman AM, Shlomchik MJ. Reassessing the function of immune-complex retention by follicular dendritic cells. Nat Rev Immunol. 2003;3(9): 757-764.
39. Kosco-Vilbois MH. Are follicular dendritic cells really good for nothing? Nat Rev Immunol. 2003; 3(9):764-769.
40. Vivier E, Daëron M. Immunoreceptor tyrosine-based inhibition motifs. Immunol Today. 1997; 18(6):286-291.
41. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol. 2005;25(1):1-18.
42. Tsang-A-Sjoe MWP, Nagelkerke SQ, Bultink IE, et al. Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology (Oxford). 2016;55(5):939-948.
43. Eckhardt CL, Astermark J, Nagelkerke SQ, et al. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A. J Thromb Haemost. 2014;12(8): 1294-1301.
44. Breunis WB, van Mirre E, Bruin M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood. 2008;111(3):1029-1038.
45. Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood. 2009;114(19):4279-4282.
46. Mekontso Dessap A, Pirenne F, Razazi K, et al. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol. 2016;91(12):1181-1184.
47. Nagelkerke SQ, Tacke CE, Breunis WB, et al. Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression. Genes Immun. 2015;16(6): 422-429.
48. Redman CM, Lee S. The Kell blood group system. Transfus Clin Biol. 1995;2(4):243-249.
49. Zuckerman SH, Douglas SD. The characterization and functional significance of plasma membrane Fc receptors. CRC Crit Rev Microbiol. 1978;7(1): 1-26.
50. Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. Blood. 1998;91(7): 2369-2380.
51. van der Heijden J, Breunis WB, Geissler J, de Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol. 2012; 188(3):1318-1324.
52. Gardner K, Hoppe C, Mijovic A, Thein SL. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol. 2015;170(6):745-756.
53. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062-1064.
54. Li X, Wu J, Ptacek T, et al. Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sci Transl Med. 2013;5(216):216ra175.
55. Li SS, Gilbert PB, Tomaras GD, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest. 2014; 124(9):3879-3890.
56. Peng X, Li SS, Gilbert PB, Geraghty DE, Katze MG. FCGR2C polymorphisms associated with HIV-1 vaccine protection are linked to altered gene expression of Fc-g receptors in human B cells. PLoS One. 2016;11(3):e0152425.
57. Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R. IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood. 2002; 99(8):2662-2669.
58. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev. 2010;236:265-275.
59. Warmerdam PA, Nabben NM, van de Graaf SA, van de Winkel JG, Capel PJ. The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event. J Biol Chem. 1993;268(10):7346-7349.
60. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol. 2015;5:674.
61. Lassaunière R, Tiemessen CT. Variability at the FCGR locus: characterization in Black South Africans and evidence for ethnic variation in and out of Africa. Genes Immun. 2016;17(2):93-104.
62. Floto RA, Clatworthy MR, Heilbronn KR, et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med. 2005;11(10):1056-1058.
63. Nielsen KR, Koelbaek MD, Varming K, Baech J, Steffensen R. Frequencies of HNA-1, HNA-3, HNA-4, and HNA-5 in the Danish and Zambian populations determined using a novel TaqMan real time polymerase chain reaction method. Tissue Antigens. 2012;80(3):249-253.
64. Chu ZT, Tsuchiya N, Kyogoku C, et al. Association of Fcgamma receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in Chinese: a common susceptibility gene in the Asian populations. Tissue Antigens. 2004;63(1):21-27.
65. Siriboonrit U, Tsuchiya N, Sirikong M, et al. Association of Fcgamma receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. Tissue Antigens. 2003;61(5):374-383.
66. Bux J, Stein EL, Bierling P, et al. Characterization of a new alloantigen (SH) on the human neutrophil Fc gamma receptor IIIb. Blood. 1997;89(3): 1027-1034.
67. Matsuhashi M, Tsuno NH, Kawabata M, et al. The frequencies of human neutrophil alloantigens among the Japanese population. Tissue Antigens. 2012;80(4):336-340.
68. Tong Y, Jin J, Yan L, Neppert J, Marget M, Flesch BK. FCGR3B gene frequencies and FCGR3 variants in a Chinese population from Zhejiang province. Ann Hematol. 2003;82(9):574-578.
69. Osborne JM, Chacko GW, Brandt JT, Anderson CL. Ethnic variation in frequency of an allelic polymorphism of human Fc gamma RIIA determined with allele specific oligonucleotide probes. J Immunol Methods. 1994;173(2): 207-217.
70. Kaset C, Leetrakool N, Intharanut K, Nathalang O. Frequency of FCGR3B alleles in Thai blood donors. Ann Lab Med. 2013;33(6):426-430.
71. Adu B, Dodoo D, Adukpo S, et al. Fc g receptor IIIB (FcgRIIIB) polymorphisms are associated with clinical malaria in Ghanaian children. PLoS One. 2012;7(9):e46197.
72. Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J Mol Med (Berl). 2002;80(4): 248-257.